Coverage and reimbursement are the payment-control layer for aging-driven health-care demand. This node covers insurers, pharmacy benefit managers, and exchange-focused health plans that price coverage, approve or deny services, manage pharmacy benefits, settle risk adjustment, and collect premiums or fees before care activity can become company revenue. The current basket read ranks UNH, ELV, and HUM highest for source-backed payer exposure, with CVS and CI as vertical PBM and commercial-benefit gates, CNC as the Medicaid and ACA repair test, and OSCR as the highest-beta ACA tail.
What the stack is: the payer and pharmacy-benefit control layer that sits between patients, employers, CMS, state Medicaid agencies, providers, pharmacies, drug manufacturers, and care-service vendors.
What it does: converts enrollment, claims, pharmacy scripts, risk scores, state rates, CMS payments, and employer contracts into premiums, administrative fees, PBM spread or service economics, risk-adjustment transfers, operating margin, and operating cash flow.
Main pieces: Medicare Advantage bids and Stars ratings, Medicaid capitation rates, ACA exchange premiums and subsidies, commercial ASO and risk contracts, Part D and PBM contracts, prior authorization, provider networks, reserves, reinsurance, and statutory capital.
Where it sits: operationally upstream of providers and pharmacies. The companies do not deliver every service themselves; they decide pricing, benefits, network access, pharmacy terms, and risk pools before claims are paid.
How the theme uses it: aging raises care utilization, but shareholders benefit only when rates, bids, premiums, rebates, and risk adjustment cover claims cost and still leave recurring earnings or cash.
Terms used below: MCR, MBR, BER, HBR, and MLR all measure medical claims or benefits as a share of premium revenue; lower is usually better if it does not come from low-quality coverage loss. Risk adjustment transfers premium between plans based on member morbidity. Stars ratings affect Medicare Advantage bonus payments and bids.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, confirmation evidence, stale setup caveats, and chart provenance. Durable research, claim IDs, raw source registries, and sector thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Main readPayer repricing is available, but Q2 claims and policy evidence must prove the repair.
CMS rate support, company guide raises, and Q1 MCR/BER/MBR/HBR evidence give the node a repair path. The setup weakens if utilization, risk adjustment, PBM remedies, ACA subsidy risk, or Medicaid rate lag absorbs the revenue bridge.
Signal 1Formal pricing levers
MA bids, state rates, ACA premiums, and PBM contracts can reset economics faster than care demand changes.
Signal 2Core proof is claims ratio
UNH MCR, ELV BER, HUM benefit ratio, CVS MBR, CNC HBR, and OSCR MLR decide whether demand converts.
Signal 3Policy can reverse the bridge
ACA subsidies, Medicaid work rules, Stars, RADV, prior authorization, and PBM scrutiny are live gates.
DemandOlder members use more care
PriceRates, bids, premiums, PBM terms
Claim costMCR, BER, MBR, HBR, MLR
Shareholder proofSegment profit and cash flow
Aging raises the amount of care consumed, but this node decides who gets paid for that care and who absorbs the bill. CMS reports 2024 national health expenditures of $5.3 trillion and projects 2024-2033 NHE growth of 5.8% a year, faster than projected GDP growth of 4.3%; CMS also shows 65+ per-person health spending far above younger cohorts. That demand helps shareholders only if premiums, CMS rates, Medicaid rates, PBM contracts, and risk adjustment turn claims activity into underwriting margin, segment profit, and operating cash flow.
The strongest support is that payers have formal repricing tools. CMS finalized a 2.48% average 2027 Medicare Advantage payment increase, or 4.98% including expected risk-score trend, which gives plans a bid input for 2027. Several company lanes also show repair evidence: UNH has an 83.9% Q1 2026 MCR and strong cash generation but needs durability; ELV raised guidance while carrying a specific CMS accrual watch; HUM has direct MA membership torque but must prove Stars and benefit-ratio repair; CVS, CI, CNC, and OSCR all have recovery evidence that still depends on cost trend, risk adjustment, PBM economics, and cash quality. The next proof point is Q2 and Q3 payer reporting that keeps MCR, MBR, BER, HBR, or MLR inside guidance without lower-quality membership growth.
The main headwind is that utilization can be a cost before it becomes earnings. ACA subsidy expiration or extension, Medicaid work requirements, risk-adjustment scrutiny, Stars exposure, PBM regulation, RADV/legal matters, and benefit cuts can turn more covered lives into weaker risk pools, higher medical-cost ratios, or lower retention. Watch Q2 and Q3 medical-cost trend, 2027 bid and benefit design, state Medicaid rate updates, ACA enrollment quality, PBM and RADV disclosures, and whether operating cash flow proves the earnings bridge.
Right-rail charts use weekly bars aggregated from discovery daily_ohlc through 2026-06-12. Static setup thresholds in the prior page were computed through 2026-06-11 and are stale after the 2026-06-12 local row; refresh chart levels before using them as current trading evidence.
Basket
This basket is hand-curated from the parent theme, linked knowledge coverage, read-only discovery coverage, and bounded official-source checks. Ranking uses source-backed exposure to payment-control economics first, then financial quality and chart timing. MOH and ALHC remain watch names because they have current market data and useful node relevance, but no filed local security lanes.
Broadest payment-control read because UnitedHealthcare prices benefits while Optum adds care, pharmacy, and services economics.
Market cap$371B
Next earningsNot confirmed
Latest qtr revenue$111.721B
Role in stack
Employers, CMS, states, and members fund UnitedHealthcare premiums or fees. Optum converts care delivery, pharmacy, data, and services work into segment revenue; MCR, Optum margins, risk adjustment, PBM scrutiny, and legal/regulatory outcomes gate conversion.
Revenue mix
UnitedHealthcare plus Optum Health, Optum Rx, and Optum Insight. Q1 2026 UnitedHealthcare revenue was $86.265B; Optum Rx revenue was $35.736B.
Latest qtr revenue
Q1 2026 total revenue was $111.721B, from the filed UNH security lane and Q1 2026 company release/10-Q source route.
Scaled Blues and Carelon platform with direct evidence in benefit expense ratio, Medicaid rates, CMS risk adjustment, and services margin.
Market cap$87.7B
Next earningsNot confirmed
Latest qtr revenue$49.494B
Role in stack
Commercial employers, Medicaid agencies, Medicare members, FEP customers, and fee-based clients fund premiums, ASO fees, pharmacy services, and care-services revenue. BER, Medicaid acuity, CMS/RADV exposure, and Carelon operating gain control the bridge.
Revenue mix
Health Benefits is the anchor, with CarelonRx and Carelon Services as pharmacy, behavioral, specialty, home-based, payment-integrity, and data-service routes. Q1 Health Benefits revenue was $42.49B.
Latest qtr revenue
Q1 2026 operating revenue was $49.494B, from the ELV lane's Q1 2026 10-Q and earnings-release source route.
Purest Medicare Advantage aging-demand gate, but Q2 claims, Stars recovery, and 2027 bid design must validate the rebound.
Market cap$45.5B
Next earningsNot confirmed
Latest qtr revenue$39.648B
Role in stack
CMS benchmarks, risk scores, Stars, bids, benefit design, Part D, and CenterWell decide whether senior utilization becomes margin or cost. The gate is benefit ratio, member quality, retention, CenterWell cost ratio, and RADV/legal containment.
Revenue mix
Insurance dominates. FY2025 individual Medicare Advantage represented 70.3% of premiums and services revenue; CenterWell adds pharmacy, primary-care, and home-solutions economics.
Latest qtr revenue
Q1 2026 total revenue was $39.648B, from the HUM lane's Q1 2026 10-Q source route.
Aetna, Caremark, and retail pharmacy make CVS a vertical coverage and pharmacy gate with useful but still messy recovery evidence.
Market cap$130B
Next earningsNot confirmed
Latest qtr revenue$100.426B
Role in stack
Aetna members, employer and PBM clients, Part D/MA-PD lives, and pharmacy customers pay through premiums, PBM contracts, scripts, specialty/mail pharmacy, and reimbursement terms. MBR, Caremark margin, retail reimbursement, and leverage gate the economics.
Revenue mix
Health Care Benefits, Health Services/Caremark, and Pharmacy & Consumer Wellness. Q1 HCB revenue was $35.971B; Health Services revenue was $48.237B.
Latest qtr revenue
Q1 2026 total revenue was $100.426B, from the CVS lane's Q1 2026 10-Q and earnings-release source route.
Commercial benefits plus Evernorth PBM scale give CI strong financial quality, with less direct aging exposure than the MA-heavy names.
Market cap$78.8B
Next earningsNot confirmed
Latest qtr revenue$68.494B
Role in stack
Employers, health-plan clients, specialty-drug customers, and commercial members pay Evernorth and Cigna Healthcare through PBM, specialty, pharmacy, administrative, premium, and stop-loss economics. Evernorth margin and Cigna Healthcare MCR are the main gates.
Revenue mix
Evernorth is the revenue engine after the Medicare and CareAllies sale. Q1 2026 Evernorth adjusted revenue was $58.442B; Cigna Healthcare adjusted revenue was $11.477B.
Latest qtr revenue
Q1 2026 total revenue was $68.494B, from the CI lane's Q1 2026 release and 10-Q source route.
Medicaid and ACA public-program exposure makes CNC a direct repair test after the 2025 Marketplace risk-adjustment break.
Market cap$32.2B
Next earningsNot confirmed
Latest qtr revenue$49.944B
Role in stack
State Medicaid agencies, CMS, and exchange members fund capitation, premiums, risk adjustment, PDP/Medicare payments, and state rate updates. HBR, Medicaid rate adequacy, Marketplace morbidity, and risk-adjustment accruals decide the recovery.
Revenue mix
Medicaid is the largest base, with Medicare/PDP and Commercial/Marketplace adding policy sensitivity. Q1 Medicaid revenue was $28.885B; Medicare was $10.326B; Commercial was $9.556B.
Latest qtr revenue
Q1 2026 total revenue was $49.944B, and premium/service revenue was $44.655B, from the CNC lane's Q1 2026 10-Q and release route.
ACA exchange concentration makes OSCR the high-beta tail where membership growth must survive claims seasonality and risk-adjustment true-ups.
Market cap$7.5B
Next earningsNot confirmed
Latest qtr revenue$4.647B
Role in stack
Members, subsidies, premiums, risk adjustment, ICHRA adoption, reinsurance, and regulated capital decide whether ACA exchange growth becomes underwriting margin and cash. The gate is MLR normalization, member quality, risk-adjustment payable accuracy, and capital flexibility.
Revenue mix
One-segment ACA marketplace platform. Revenue is dominated by premium revenue, medical claims, ACA risk-adjustment transfers, exchange rules, reinsurance, regulated capital, and SG&A.
Latest qtr revenue
Q1 2026 total revenue was $4.647B, from the OSCR lane's Q1 2026 10-Q and company release route.
Market caps are approximations computed from local discovery instrument weighted shares and the latest local daily_ohlc close on 2026-06-12. Next earnings dates are marked Not confirmed because official IR calendars and Nasdaq earnings pages checked on 2026-06-13 did not provide confirmed future dates. Latest-quarter revenue uses reported Q1 2026 total revenue from the linked security lanes and company filing/release routes.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
1Node thesisPayment control
What confirms
MCR, MBR, BER, HBR, or MLR stays inside guidance while revenue, segment profit, and operating cash flow improve.
What weakens or invalidates
Utilization or acuity rises faster than rates, bids, premiums, risk adjustment, PBM contracts, or services economics.
Watch next
Q2 payer reports
Q3 medical trend
Segment cash conversion
2Economics mechanismRates to margin
What confirms
2027 MA bids, Medicaid rates, ACA risk adjustment, Stars, Part D mechanics, and PBM contracts support margins without large member losses.
What weakens or invalidates
Benefit cuts, county exits, adverse risk-adjustment true-ups, PBM remedies, or adjusted earnings fail to become recurring cash.
Watch next
2027 bids
Stars
Final risk adjustment
OCF versus guide
3Customer and risk poolMember quality
What confirms
Membership growth or retention comes with stable morbidity, adequate pricing, controlled risk adjustment, and no material rise in denials, appeals, or churn.
What weakens or invalidates
Growth concentrates in weaker ACA, Medicaid, or MA cohorts, or benefit changes protect margin only by damaging retention and future risk mix.
Watch next
MA retention
ACA morbidity
Medicaid acuity
Complaint and denial trends
4Funding and capitalCash quality
What confirms
Operating cash flow funds regulated capital, debt reduction, dividends, buybacks, and systems investment without raising per-share risk.
What weakens or invalidates
Leverage, ratings pressure, statutory capital needs, converts, reinsurance dependence, parent cash limits, or litigation payments absorb earnings.
Watch next
Debt-to-capital
Ratings
Statutory surplus
Capital returns
5Policy and regulationApproval gates
What confirms
CMS MA rate support, state Medicaid actions, prior-authorization rules, ACA rules, and PBM scrutiny stay inside management's margin and cash-flow frameworks.
What weakens or invalidates
RADV accruals, prior-authorization sanctions, PBM settlements, Medicaid work requirements, or ACA subsidy loss damages risk pools or margins.
Watch next
CMS/RADV
FTC/PBM
State Medicaid
ACA rules
6Operating constraintExecution
What confirms
Optum, Carelon, CenterWell, Caremark, Evernorth, Medicaid, and ACA operations show margin, claims, risk-adjustment, and service-cost evidence consistent with guidance.
What weakens or invalidates
Services revenue grows without operating gain, PBM client economics reset lower, CenterWell or Carelon costs rise, or risk-adjustment accruals move against prior estimates.
Watch next
Segment margins
Risk-adjustment payables
PBM model changes
Service cost ratios
7Stale conditionRefresh trigger
What confirms
Security lanes, source trail, earnings-date checks, and daily_ohlc remain current before exact setup levels are reused.
What weakens or invalidates
Watch names without local lanes are treated as researched core names, confirmed earnings dates appear, Q2 evidence arrives, or static chart thresholds are used without refresh.
Read-only discovery coverage checks used daily_ohlc rows from ../discovery/data/discovery.duckdb. UNH, ELV, HUM, CVS, CI, CNC, OSCR, MOH, and ALHC had local rows through 2026-06-12.
Weekly bars group daily rows by calendar week: first open, maximum high, minimum low, final close, and summed volume.
Right-rail API charts use 20-week and 100-week EMAs computed from weekly closes before clipping the visible three-year chart window, with a volume subgraph. Static setup rows from the old page were computed through 2026-06-11 and are stale after the 2026-06-12 local row.
The right-rail chart contract is /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. Node HTML does not embed OHLC arrays.
Review API validation on 2026-06-13 started python -m api.run, but a separate curl to /api/securities/UNH/chart?frequency=weekly&window=3y&as_of=latest still could not connect to 127.0.0.1:8765. Static API attributes, chart triggers, route metadata, and absence of embedded OHLC payloads were validated.
Representative discovery status check: discovery status UNH --json showed 1,278 daily bars from 2021-05-12 through 2026-06-12. A read-only DuckDB coverage query checked UNH, ELV, HUM, CVS, CI, CNC, OSCR, MOH, and ALHC.
Market-cap metric source: local discovery instruments.weighted_shares_outstanding multiplied by the latest 2026-06-12 daily_ohlc.close; rounded values are used in the basket cards.
Earnings-Date And Revenue Checks
Next earnings: no confirmed future date was found for UNH, ELV, HUM, CVS, CI, CNC, or OSCR during bounded web checks on 2026-06-13. Nasdaq earnings pages for UNH, ELV, HUM, CVS, CI, CNC, and OSCR returned no available earnings date at access time.
Latest quarterly revenue sources and periods: UNH Q1 2026 $111.721B; ELV Q1 2026 operating revenue $49.494B; HUM Q1 2026 total revenue $39.648B; CVS Q1 2026 total revenue $100.426B; CI Q1 2026 total revenue $68.494B; CNC Q1 2026 total revenue $49.944B; OSCR Q1 2026 total revenue $4.647B. Each amount is routed through the linked security lane and its Q1 2026 filing or company-release source route.
Known Gaps
MOH is a strong Medicaid/state-rate watch candidate with fresh local market data, but no local security lane exists at publication time.
ALHC is a creative Medicare Advantage tail with fresh local market data, but no local security lane exists at publication time.
CLOV, PRVA, EVH, and other tails were reviewed by subagents but kept out of the ranked basket because fit, source coverage, or maturity was weaker than the parent-declared core.
Q2 2026 earnings dates remain unconfirmed as of 2026-06-13. Q2 2026 earnings, 2027 bids, Stars updates, RADV/PBM developments, and ACA or Medicaid policy changes can change the node quickly. Refresh source lanes, earnings dates, and setup levels together.